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creativecommons.org/licenses/by-nc-nd/4.0/).Trachoma is a centuries-old external eye infection caused by
Chlamydia trachomatis that has affected humans since the dawn
of civilization. Before the invention of antibiotics, it was the leading
cause of corneal blindness. Even today, trachoma remains one of
the two eye diseases that are global health topics (the other is cata-
ract).1 After World War II, under the supervision and guidance of
WHO, a global campaign against trachoma gained substantial prog-
ress. This resulted in trachoma essentially being eradicated in
developed countries, and in many developing countries.
In the review article Trachoma in AsiadA disappearing scourge by
Hugh Taylor, the author presents the readers with a concise review
on the epidemiology of trachoma. This begins with trachoma infec-
tion in human history, followed by the pathogenesis of trachoma, in
which recurrent infections caused a progressive ﬁbrosis of conjunc-
tiva, cicatricial entropion, pannus formation and corneal damage
that ultimately affects the vision. When the ﬁrst International
Congress of Ophthalmology was held in 1857, trachoma was one
of the two key issues on the agenda.2 In the 20th century, trachoma
was widespread around the world up to the 1920s, but started to
disappear in most developed countries thanks to improved living
conditions and the advent of antibiotics, such as the sulfonamides
in the 1930s and tetracycline in the 1940s. As a consequence,
trachoma had disappeared from most developed areas by the
1950s and 1960s. Data presented by the author showed that iniety of Taiwan. Published by ElseviJapan trachoma essentially disappeared among school children in
the 1970s, and similar ﬁndings were reported from Taiwan.
The control of trachoma in Taiwan began from the Japanese
occupation period (1895e1945). From 1915 to 1917, the ﬁrst
island-wide investigation showed that the prevalence rate was
38.7%, with the incidence higher in southern region (48.76%) and
lower in the northern region (21.79%). Blindness caused by
trachoma was almost 3% among the general population.3 Subse-
quent studies (1922e1925, 1926e1929, and 1935) revealed that
the prevalence rate had been approximately 35%. The Japanese
colonial government started some control and treatment projects
in endemic areas after the 1920s. However, limited by the availabil-
ity of antibiotics, the control effect was not signiﬁcant during that
period.
It was after World War II, with the assistance of WHO and UNI-
CEF, that marked a new era of trachoma control in Taiwan. In 1952,
a pilot project supervised by WHO was started, which showed
that topical treatment with 1% aureomycin or terramycin for 2
months was successful for most cases, and oral sulfonamide was
effective for cases refractory to topical treatment. In 1954 a Center
for Trachoma Prevention and Treatment was established in the
Taiwan Provincial Government. This center served as a hub for ed-
ucation, and training center for primary care physicians and
nurses from local public health centers, as well as school teachers
and administrators. Few ophthalmologists were available at that
time, therefore the primary-care physicians were trained to iden-
tify active trachoma and to give treatment at schools. A massive
campaign aimed at treating all school children was conducted be-
tween 1954 and 1956. The treatment protocol was standardized,
which comprised 1% aureomycin or terramycin twice daily for
2e4 months, and combined oral sulfonamide after 2 months for
refractory cases. However, because the healed school children
often suffered from reinfection contracted from other family
members,4 after 1962 a community-wide trachoma treatment
program was instituted on the whole island.5 The children were
treated at schools, while the adults received treatment from local
public health centers. With these efforts, in 1961 the prevalence
was reduced to 13.1% in the general population, in 1968 it was
3.4%, and in 1981 it was < 1%. Since then, trachoma is no longer
a public health issue in Taiwan. When the national health insur-
ance (NHI) became available in the 1990s, statistics showed that
the number of patients treated under the diagnosis of trachoma
further decreased by 84% from 1998 to 2008. In 2008, the NHI
database showed that a total of 2317 cases nationwide (< 0.01%er Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Editorial / Taiwan Journal of Ophthalmology 6 (2016) 53e5454general population) were treated, with most patients being
elderly. This reﬂected the fact that these were old cases contracted
during their childhood, and sought medical treatment for the
long-term sequela.3
In 1997, WHO launched the WHO Alliance for the Global Elim-
ination of Trachoma by the year 2020 (GET 2020). To date,
although active trachoma still remains a problem in some coun-
tries in the AsiaePaciﬁc region, the global effort has made
trachoma rapidly diminish in these countries. In endemic areas
using the WHO-recommended SAFE strategy (surgery for
inturned lashes, antibiotic treatment, the promotion of facial
cleanliness and environmental improvement), it is very likely
that trachoma as a blinding disease can be eliminated in the
AsiaePaciﬁc region by the year 2020.Special Acknowledgment
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